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Abstract
To identify loci for age at menarche, we performed a meta-analysis of 32 genome-wide
association studies in 87,802 women of European descent, with replication in up to 14,731
women. In addition to the known loci at LIN28B (P=5.4×10−60) and 9q31.2 (P=2.2×10−33), we
identified 30 novel menarche loci (all P<5×10−8) and found suggestive evidence for a further 10
loci (P<1.9×10−6). New loci included four previously associated with BMI (in/near FTO,
SEC16B, TRA2B and TMEM18), three in/near other genes implicated in energy homeostasis (BSX,
CRTC1, and MCHR2), and three in/near genes implicated in hormonal regulation (INHBA, PCSK2
and RXRG). Ingenuity and MAGENTA pathway analyses identified coenzyme A and fatty acid
biosynthesis as biological processes related to menarche timing.
INTRODUCTION
Menarche, the onset of first menstruation in girls, indicates the attainment of reproductive
capacity and is a widely used marker of pubertal timing. Age at menarche varies widely
between girls and is highly dependent on nutritional status1. Early menarche is associated
with several adverse health outcomes, including breast cancer2, endometrial cancer3,
obesity4, type 2 diabetes5 and cardiovascular disease6, and also shorter adult stature4.
Studies of twins and extended families, albeit largely performed in populations free of
nutritional deprivation, estimate that around 50% of the variance in menarche timing is
attributable to genetic factors in such settings7.
Recently, common variants in LIN28B were associated with age at menarche in four
independent genome-wide association studies (GWAS)8–11. LIN28B is a human homolog of
lin-28 in C. elegans, which controls its rate of progression from larval stages to adult cuticle
formation, indicating the possible conservation of specific micro-RNA regulatory
mechanisms involved in developmental timing9. A second menarche locus was identified in
an intergenic region at 9q31.28,10. These two loci together explained only 0.6% of the
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variance in age at menarche8. We anticipated that a much larger GWAS would substantially
increase the yield of loci associated with age at menarche.
Here we report a much expanded meta-analysis of GWAS for age at menarche. By
combining data from the previous studies8–11 plus several further studies to form the
ReproGen Consortium, we have identified at least 30 novel loci associated with age at
menarche at genome-wide significance levels. Our findings demonstrate a close link
between the genetic regulation of energy homeostasis and pubertal timing, and suggest the
presence of other diverse pathways.
RESULTS
Genome-wide association for age at menarche
This expanded GWAS includes data from 32 cohorts of European ancestry (N=87,802). In
most studies age at menarche was determined by self-recall and the mean age at menarche in
individual studies ranged from 12.4 to 13.6 years, excluding individuals with menarche <9
and >17 years (Methods, Supplementary Table 1 and Supplementary Note). Genome-wide
SNP genotyping was performed using a variety of different platforms (Supplementary Table
2 and Supplementary Note). Therefore, after applying standard quality control measures, we
imputed the genotypes for ~2.5 million autosomal SNPs in the HapMap CEU sample using
Build 35/36 to allow inverse variance meta-analysis of additive genetic association results
from each study. We also meta-analysed results from X chromosome SNPs in studies which
had this data available (N=52,781). Test statistics from each cohort were adjusted using
genomic control to avoid inflation of results due to population stratification.
There was strong deviation from the uniform distribution of P-values expected under the
null hypothesis (Supplementary Fig. 1). This deviation was attenuated, but persisted,
following removal of those signals associated with the two previously identified loci. In
total, 945 SNPs representing 45 loci (r2 <0.05 based on HapMap in a 750 kb region) were
associated with age at menarche at genome-wide significance levels (P<5×10−8) (Fig. 1;
Supplementary Fig. 2). None of these were located on the X chromosome. These 45 loci
included three apparent second signals (defined as two genome-wide significant SNPs in
low LD (r2<0.05) in the same 750 kb region) at 2q33.1, 6q21 and 14q32.2. The second
signal at 6q21 (rs314279) had a low minor allele frequency (MAF, 6%) and was not present
in many studies. We therefore genotyped this SNP de novo in the InChianti cohort and
found it was in LD with the top chromosome 6 signal (rs7759938, r2=0.3). In HapMap the
r2 between the two chr 6 SNPs was 0.015, but the D’ was 1.0. To verify the independency of
additional loci, we performed a conditional analysis and meta-analysis of all 32 studies
using the top SNP at all the 42 genome-wide significant regions as covariates (in addition to
birth year). In these conditional analyses the possible second signals on chromosomes 2 and
14 showed strong but sub-genome-wide significant associations with age at menarche
(P<7.1×10−6), suggestive of, but not confirming, second independent signals in these two
regions (Fig. 1; Supplementary Table 3).
The two most significant loci for age at menarche confirmed the previously reported
associations at LIN28B (rs7759938; P=1.6×10−58) and 9q31.2 (rs2090409; P=4.4×10−33)
(Table 1; Supplementary Fig. 3). In addition, there were genome-wide significant signals for
a further 40 possible novel loci, of which 30 survived a second more stringent correction for
the overall genomic control in the Stage 1 cohorts (λ=1.173) (Table 1; Fig. 1;
Supplementary Fig. 3).
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Replication studies
We sought confirmation of the 40 possible novel menarche loci in up to 14,731 women from
16 additional studies with in silico GWAS data and new genotyping data from one cohort
(Supplementary Tables 4 & 5). This replication sample was substantially smaller than our
Stage 1 sample, and therefore underpowered to confirm individual SNP associations
(Supplementary Fig. 4). Nonetheless 37 of the 40 possible novel loci showed directionally
consistent associations in both stages (Table 1; binomial sign test: P=9.7×10−9). A combined
meta-analysis of the more stringent 2nd GC corrected Stage 1 results and replication cohorts
gave confirmatory evidence for 30 novel menarche loci, leaving 10 unconfirmed possible
menarche loci (Table 1; Fig. 1).
Based on combined Stage 1 plus replication results, the estimated magnitudes of per allele
effects for the novel menarche loci ranged from 4.5 to 2.1 weeks per allele (Table 1) and
demonstrated an inverse relationship with MAF (Supplementary Fig. 5). Among the four
largest in silico replication cohorts (each comprising >800 women) the variance in age at
menarche explained by all 42 known, confirmed and possible novel menarche loci ranged
from 3.6% to 6.1% (Supplementary Table 6).
Roles of genes at/near novel loci (Supplementary Table 7)
The strongest novel menarche signal was for rs1079866 (3.9 weeks/minor allele; 95% CI 2.9
to 5.0, P=5.5×10−14), approximately 250kb downstream of INHBA, which encodes the
protein subunit Inhibin beta A. Heterodimers of Inhibin beta A and the Inhibin alpha subunit
form the female reproductive hormone Inhibin A12. Inhibin A, produced by granulosa cells
in the ovary, increases dramatically during pubertal development in girls13,14 and is
involved in negative feedback regulation by inhibiting production of follicle stimulating
hormone (FSH) by the pituitary and secretion of gonadotrophin releasing hormone (GnRH)
from the hypothalamus15. Conversely, homodimers of Inhibin beta A form the hormone
Activin A, which stimulates pituitary FSH production, and also exhibits a wide range of
biological activities including the regulation of cellular proliferation and differentiation16.
The second strongest novel signal was for rs466639 (P=1.3×10−13); this SNP is intronic in
RXRG, which encodes retinoid X receptor gamma, a nuclear receptor that forms dimers with
the receptors for retinoic acid, thyroid hormone, and vitamin D, increasing both DNA
binding and transcriptional function on their respective response elements17.
Four novel loci for menarche were previously identified by GWA studies for adult
BMI18–20; these were rs9939609 (in/near FTO, P=3.1×10−8), rs633715 (SEC16B,
P=2.1×10−8), rs2002675 (TRA2B, ETV5, P=1.2×10−9) and rs2947411 (TMEM18,
P=1.7×10−8). Apart from rs2002675, these menarche signals were either identical to or in
tight LD (r2>0.9) with those BMI loci, and in all cases the BMI-increasing allele was
associated with earlier menarche. Variants at these four loci have also been associated with
childhood BMI18–20, and these findings support a likely causal effect of childhood BMI on
earlier pubertal timing.
Three novel menarche loci were found in/near further genes implicated in the regulation of
energy homeostasis and body weight in animal models: rs6589964 (P=1.9×10−12) lies
~18kb from BSX; rs10423674 (P=5.9×10−9) is intronic in CRTC1; and rs4840046
(P=2.4×10−8) lies ~160kb from MCHR2. BSX encodes a DNA binding protein and
transcriptional activator. In the mouse Bsx is expressed specifically in the pineal gland,
telencephalic septum, hypothalamic pre-mammillary body and arcuate nucleus, and is
necessary for postnatal growth, locomotory behaviour, expression of the genes Npy and
Agrp, and for the hyperphagic phenotype in leptin deficiency21. CRTC1 encodes the CREB
regulated transcription coactivator 1, an activator of cellular gene expression. Crtc1(−/−)
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mice are hyperphagic, obese and infertile, and females have low circulating luteinizing
hormone levels22. Leptin potentiates the effects of Crtc1 transcriptional activity, and Crtc1
over-expression in hypothalamic cells increases expression of Kisspeptin, which in turn
activates secretion of gonadotrophin releasing hormone Kiss1 gene. MCHR2 encodes the
melanin concentrating hormone receptor 2, an orphan G protein-coupled receptor which
shows high affinity binding to the hypothalamic neuropeptide melanin-concentrating
hormone (MCH), which regulates nutrient intake and energy homeostasis via MCHR123.
Furthermore, MCH directly inhibits GnRH neurons and thereby links energy balance to
reproduction24.
rs852069 (P=3.3×10−8) lies ~84kb from PCSK2, which encodes proprotein convertase
subtilisin/kexin type 2, an enzyme that cleaves latent precursor proteins, such as proinsulin
and proopiomelanocortin, into their biologically active products. While rare deleterious
mutations and common variants in PCSK1 are known to influence obesity risk, it is notable
that PCSK2 differs from PCSK1 in that it additionally cleaves proluteinizing-hormone-
releasing hormone and could therefore have a more direct influence on the reproductive
hormone axis.
Pathway analyses
Remaining novel menarche loci were found in or near to genes that are involved in a
seemingly diverse range of biological functions (Supplementary Table 7). We used
Ingenuity Pathway Analysis (IPA) to identify potential biological pathways common to
these identified loci. Based on direct interactions only, we identified two significant
functional networks containing 16 and 11 genes, respectively, of those genes nearest to the
novel menarche loci (Supplementary Fig. 6). Network 1, related to “Gene Expression,
Cellular Growth and Proliferation, Cellular Function and Maintenance”, covers a wide and
non-specific range of biological pathways. Functions in Network 2 relate to “Lipid
Metabolism, Small Molecule Biochemistry and Molecular Transport” (Supplementary Table
8). Central to Network 2 are RXRG and several genes involved in fatty acid biosynthesis,
including several fatty acid binding proteins and ACSL1, which encodes a enzyme that
converts free long-chain fatty acids into fatty acyl-CoA esters.
To identify potential further biological pathways that influence menarche timing, we used a
gene set enrichment analysis (GSEA) approach in MAGENTA, in which each gene in the
genome is assigned an adjusted score that represents its association with age at menarche,
and predefined pathways are tested for enrichment of multiple associations (see Methods).
The most significant pathway was the biosynthesis of Coenzyme A, which is a carrier of
acyl groups and is necessary for pyruvate oxidation and fatty acid synthesis and oxidation
(Supplementary Table 9).
Functional SNP and structural assessment
We explored the potentiallyfunctional impacts of our novel menarche loci in order to
identify their likely genetic mechanisms. In addition, by particularly focusing on those
groups of SNPs that have been identified as functional, we aimed to identify possible further
menarche loci, which did not reach genome-wide significance in our primary meta-analysis.
Copy Number Variation—Using data from a recent genomic map of Copy Number
Variation (CNV)25, we established that none of the 42 known, confirmed or possible novel
menarche loci were related to CNVs. Next we explored the 1,052 CNV tagging SNPs for
association with age at menarche in our GWAS sample. Only one tag SNP was associated
with age at menarche after Bonferroni correction (rs3101336, P=3×10−7; Supplementary
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Fig. 7). This SNP tags a CNV near to the NEGR1 gene locus, which has been previously
associated with body mass index20.
Non-synonymous SNPs—None of the 42 known, confirmed or possible novel menarche
variants were amino acid changing. However two were in strong LD (r2≥0.8) with non-
synonymous (ns) variants. rs1862471 (intronic in OLFM2 at 19p13.2) is in LD (r2=0.8) with
rs2303100, which encodes an Arg/Gln residue change in OLFM2. Secondly, rs4929923
(3′UTR of TRIM66 at 11p15.4) is in LD (r2=0.92) with rs11042023, which encodes a His/
Arg residue change in TRIM66.
To identify possible further menarche loci we then explored the set of 12,062 ns-SNPs for
association with age at menarche in our GWAS sample. Outside of the already associated
regions, three ns-SNPs were associated with age at menarche after correction for multiple
testing (Bonferroni threshold for 12,062 independent tests was P<4.1×10−6). These ns-SNPs
were rs1254319 in C14orf39 (P=1.9×10−7), rs7653652 in C3orf38 (P=1.4×10−6) and
rs913588 in JMJD2C (P=3.3×10−6).
Expression QTLs—Three of the 42 known, confirmed or possible novel menarche
variants were highly significantly cis-associated with mRNA expression (P<1×10−6 for
mRNA transcript abundance), based on publicly available data from lymphoblastoid cell
lines on 400 children (mRNA by SNP Browser). These transcripts were in GAB2 (associated
with rs10899489), RBM6 (rs6762477) and NARG2 (rs3743266) (Supplementary Table 10).
As these genomic loci included a number of genes (Supplementary Fig. 3), these specific
transcript associations inform the likely functional gene at each locus.
Given the likely close biological interaction between the regulation of age at menarche and
adiposity, we hypothesized that adipose tissue eSNPs might show a preponderance of
associations with age at menarche. Of the 5,184 adipose eSNPs identified in the Icelandic
Family Adipose cohort26, 23 were significantly associated with age at menarche after
correction for multiple testing (using a 1/n P-value threshold for 5,184 independent tests
(P<1.9 × 10−4)) (Supplementary Table 11). Of these adipose eSNPs, rs10835211 (menarche
P-value=9.4×10−6) is near BDNF, which is a BMI locus and is implicated in eating behavior
and body weight regulation27,28. rs7160413 (menarche P-value=2.2×10−5) is near DLK1, a
gene implicated in early onset puberty29. rs133934508 (menarche P-value=3.6×10−5) is
associated with expression of PITX1, which encodes a pituitary transcriptional regulator30.
Candidate gene assessment
Candidate gene studies for age at menarche have largely focussed on genes involved in sex
steroid-hormone biosynthesis and metabolism, highlighted through animal models or human
cases with extreme delayed puberty or hypogonadotrophic hypogonadism31. We examined
8,770 SNPs in 16 candidate genes31–33 and their surrounding regions (+/−300kb) for
association with age at menarche in our GWA meta-analysis sample (Supplementary Table
12). SNPs in the regions of TAC3R (top hit: rs17034046; P=3.4×10−7, ~19kb upstream of
TAC3R) and ESR1 (top hit: rs9383922; P=2.2×10−6, 110kb upstream of ESR1) were
significantly associated with age at menarche after correction for multiple testing
(Bonferroni threshold for 8,770 independent tests was P<5.7×10−6). Rare deleterious
mutations in TAC3R, encoding a receptor for Neurokinin B, and in its ligand TAC3 have
been found in families affected by hypogonadotropic hypogonadism and pubertal failure31.
ESR1 encodes an estrogen receptor that is essential for sexual development and reproductive
function, and polymorphisms in ESR1 have previously been nominally associated with age
at menarche33.
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Overlapping heritability of body size and menarche timing
Family studies have suggested a substantial co-inheritance of the timing of puberty and
BMI34, and this is supported by our finding of four established BMI variants among our
novel menarche loci. We therefore systematically assessed whether established loci for
adiposity-related traits (BMI, waist-hip ratio (WHR) and obesity), and adult height, were
also associated with age at menarche. Nine of the 12 BMI loci and 2 of the 4 WHR loci
tested were associated with age at menarche (Table 2 and Supplementary Table 13). In all
cases the BMI- or WHR-increasing allele was associated with earlier menarche, which is
consistent with the direction of association in epidemiological studies35. 11 of the 44 adult
height loci were associated with age at menarche (Table 3 and Supplementary Table 14).
However, for 7 of these loci, the adult height-increasing allele was associated with earlier
menarche, which is in the opposite direction to the association in individual-level
epidemiological studies35.
We then assessed the relevance of our novel menarche loci to adult BMI and height by
exploring in silico data from the GIANT consortium. Nine of the 42 menarche loci were
associated with adult BMI (at P<0.05; N=32,530); in all cases the allele associated with
higher BMI was associated with earlier menarche (Supplementary Table 15). Eighteen of the
menarche loci were associated with adult height (at P<0.05; N~130,000); although for three
of these the direction of effect was opposite to that predicted from epidemiological studies
(Supplementary Table 16). Despite these joint associations with body size, in ALSPAC
mothers the combined influence of the menarche loci on age at menarche appeared to be
completely unattenuated following adjustment for adult height and BMI (Supplementary
Table 17) suggesting that in general these menarche loci have direct effects on age at
menarche. However, we acknowledge that further large studies with childhood growth data
are needed to establish the causal directions of effect of these loci.
DISCUSSION
In a large GWAS meta-analysis comprising over 87,000 women, we identified 30 novel loci
for the timing of menarche, and provide evidence for a further 10 possible novel loci. These
loci were in/near genes associated with cellular development, body weight regulation,
hormonal regulation and with a wide varietyof other biological functions. Previous studies
comprising up to 17,510 women had detected only one or two genome-wide significant
signals8–11. We now show that those earlier signals at LIN28B and 9q31.2 represented the
‘low-hanging fruit’ with particularly large effect sizes relative to their MAF (Supplementary
Fig. 5). The list of functions of those genes nearest to the menarche loci (Supplementary
Table 7) and the results of pathway analyses indicate a wide diversity of biological
processes that regulate the timing of female pubertal maturation.
Among the confirmed novel menarche loci were several loci implicated in body weight
regulation, including four loci with established associations with BMI (in/near FTO,
SEC16B, TRA2B and TMEM18). Furthermore, our systematic analysis of established BMI-
related SNPs showed that the majority of alleles related to higher BMI and waist-hip ratio
also showed at least nominal associations with earlier menarche (Table 2). It is noteworthy
that three novel menarche loci are in/near genes implicated in energy homeostasis in animal
models (BSX, CRTC1, and MCHR2). In the GIANT consortium data, we did not detect any
associations between these loci and adult BMI however the BSX and MCHR2 loci were
nominally associated with adult height. In order to robustly investigate whether menarche
loci have pleiotropic effects on growth, or whether the association with menarche timing is
driven through increased adiposity, measures of body fatness prior to menarche, or even
prior to the onset of puberty would be required, but were unavailable in most studies.
Further functional studies of these novel menarche loci may also help to clarify the
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biological mechanisms linking these traits. In addition to influencing the timing of pubertal
initiation, sufficient adiposity is also required for the maintenance of normal hypothalamic-
pituitary-gonadal function, via signalling by adipocytokines such as leptin36.Our pathway
analyses highlighted Coenzyme A and fatty acid biosynthesis as biological pathways related
to menarche timing. Hypothalamic levels of long-chain fatty acyl-Coenzyme As have been
shown to regulate rodent feeding behaviour and glucose homeostasis37 and genetic variants
in this pathway could therefore potentially alter central nutrient sensing.
Earlier age at menarche is related to shorter adult stature in large epidemiological studies35.
We found that several adult height-increasing alleles were also associated with age at
menarche (Table 3), but at different loci these alleles were associated with either earlier or
later menarche. These paradoxical associations suggest a complex inter-play between
growth and pubertal timing. Earlier menarche is associated with taller, rather than shorter,
childhood height, and there are likely separate causal effects of rapid linear growth on earlier
puberty, and of earlier pubertal maturation on earlier growth plate fusion and cessation of
growth.
While our pathway analyses strongly identified potential new biological pathways involved
in pubertal timing, we acknowledge that the ability to assign putative functions to these
menarche loci is substantially limited by the lack of identification of the causal variant at
each locus. Many of the strongest associated SNPs were located 100’s of kb distant to the
nearest gene, and some menarche loci contained several plausible genes. Indeed, none of the
top signals represented non-synonymous SNPs, and only two were in LD with such variants
(in OLFM2 and TRIM66). Use of eQTLs helped to identify the likely causal genes (GAB2,
RBM6 and NARG2) at three menarche loci that spanned multiple genes. However, much
future work will be required to identify the causal variants and implicated genes related to
these menarche loci.
Despite the large size of our meta-analysis and the substantial increase in the number of
menarche loci, these together explained between 3.6–6.1% of the variance in age at
menarche, equivalent to 7.2–12.2% of its heritability. The majority of menarche loci had
estimated effect sizes of between 2 to 3 weeks per allele. Assuming the presence of many
true menarche SNPs with an effect size of 2 weeks per allele, even our large meta-analysis
would only have had sufficient power to detect half of those SNPs with a MAF of 50%, and
only 1 in 10 of those SNPs with MAF of 10% (Supplementary Fig. 8).
We corrected for population stratification by applying the genomic control method38 to each
of the individual study results. When we applied a more stringent second correction for the
overall genomic control inflation factor across all 32 studies, 10 of the 40 possible novel
menarche variants fell below genome-wide significance (Fig. 1; Table 1). However, our
subsequent finding of confirmatory evidence (P<0.05) even in our limited replication studies
for 4 of these 10 variants (in/near TRIM66, TMEM108, TMEM18 and NFAT5) suggests that
the second correction for genomic control is likely to be over-conservative.
Our identification of strong associations with SNPs near to the candidate genes TAC3R and
ESR1 supports the likely presence of further menarche loci, which did not meet the genome-
wide significance threshold. Systematic assessment of functional genetic variants identified
several further putative menarche loci. rs3101336, which tags a CNV near the BMI locus
NEGR1, showed strong, but sub-genome-wide significant, association with age at menarche
(P=3×10−7). Exploration of adipose tissue eQTLs also identified further putative menarche
loci related to genes implicated in eating behaviour (BDNF), precocious puberty (DLK1) and
pituitary function (PITX1). It has been suggested that lower levels of statistical significance
may be applied to variants with prior biological candidacy, however this must be balanced
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against the desire to avoid false positives, and we suggest that these putative menarche loci
require confirmation in further studies.
Notably all of the top menarche variants had MAF ≥7%. While it has been suggested that
low-frequency variants have larger effects than common variants39, we were clearly
underpowered to detect low-frequency variants (MAF <5%) with modest effect sizes. It is
also possible that rare variants are not well captured using genome-wide chips. Future re-
imputation using deep sequencing data from the 1000 Genomes Project may identify
additional low frequency hits as well as refining the location of possible functional variants.
In the majority of studies contributing to this report, age at menarche was recalled several
years later, and often to the nearest completed whole year. Although recalled age at
menarche is valid40, and is unlikely to show systematic bias by genotype, any non-
differential error would lead to reduced statistical power. Menarche indicates the completion
of puberty in females and it is unclear whether our novel menarche loci also influence
timing of other pubertal phenotypes. The known menarche locus in LIN28B was shown to
also influence the onset of breast development in girls, the timing of pubic hair development
and voice breaking in boys9, and the timing of the pubertal growth spurt in both boys and
girls41. While our novel menarche loci might also regulate such wider pubertal processes, it
is plausible that some (e.g. INHBA) might have sex-specific effects. Our study was restricted
to cohorts of European ancestry and our results are therefore not generalized to other groups.
African American girls tend to show earlier pubertal maturation compared to girls of White
European ancestry42 and genetic studies in such populations might reveal different
menarche loci.
In summary, we identified at least 30 novel loci for age at menarche. Our findings
demonstrate the role of genes which regulate energy homeostasis and hormone pathways,
and illustrate the complexity of the regulation of the timing of puberty.
METHODS
Stage 1 GWAS populations
Thirty-two studies contributed to the Stage 1 GWAS meta-analysis, comprising 87,802
women of White European ancestry. The consortium was made up of populations from the
Age, Gene/Environment SusceptibilityStudy(AGES, n=1849), the Amish population
(Amish, n=557), the Atherosclerosis Risk in Communities study (ARIC, n=4247), the
British 1958 Birth Cohort (B58C-T1DGC and B58C-WTCCC, n=1584), CoLaus (n=2797),
deCODE (n=15,864), the Danish National Birth Cohort (DNBC, n=1748), the Estonian
Genome Center, University of Tartu (EGCUT, n=987), the European Prospective
Investigation into Cancer and Nutrition (EPIC-obesity cases and cohort, n=1840), the
Erasmus Rucphen Family Study (ERF, n=1103), the Framingham Heart Study (FHS,
n=3801), the Helsinki Birth Cohort (HBCS, n=976), the Health 2000 study (Health 2000
cases and controls, n=922), InCHIANTI (n=597), the Indiana University premenopausal
Caucasian women peak BMD study (Indiana, n=1497), the Nurse’s Heath Studies (NHS,
n=5360), the Northern Finland Birth cohort (NFBC, n=2648), the Netherlands Twin
Register (NTR, n=1051), the Queensland Institute of Medical Research (QIMR, n=3528),
the Rotterdam studies (RS1, RS2 and RS3, n=5406), the Study of Addiction: Genetics and
Environment (SAGE, n=1376), the SardiNIA study (n=2158), Twins UK I, II and III
(n=3962) and the Women’s Genome Health Study (WGHS, n=22,028). Full details can be
found in the Supplementary note. All studies were approved by local ethics committees and
all participants provided written informed consent.
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Phenotype measurement and inclusion criteria
Age at menarche recalled by the participant was recorded in each study. Specific questions
asked can be found in Supplementary Table 1. Only women of White European ancestry
with a valid age at menarche between 9 and 17 years were included in this analysis, since
this represents the normal physiological range. Information on birth year was also collected
in each study.
Genotyping
The 32 Stage 1 studies were genotyped using a variety of Affymetrix (6.0, GeneChip 500K,
250K, MIP50K and 10K) and Illumina (HumanHap 550K, 318K, HumanHap 300K,
HumanHap 370K CNV, HumanHap610 quad, Human660W-Quad BeadChip, 6K and
Human 1Mv1_C) genotyping arrays. Genotyping call rate cut-offs were at least 90% and
SNPs were filtered for those with a minor allele frequency of greater than 1%. More details
on the filtering criteria for genotypes in each individual study can be found in
Supplementary Table 2.
Genotype imputation
In order to increase genomic coverage and allow the evaluation of the same SNPs across as
many study populations as possible, each study imputed genotype data based on the
HapMap CEU Build 35 or 36. Algorithms were used to infer unobserved genotypes in a
probabilistic manner in either MACH, IMPUTE43, or software that was developed by the
researchers. As a quality control measure, we excluded non-genotyped SNPs with an
imputation quality less than 0.3 (for observed versus expected variance in MACH) or 0.4
(for IMPUTE’s proper info statistic) from the meta-analysis.
Association testing
Each study performed genome-wide association testing for age at menarche across
approximately 2.5 million SNPs, based on linear regression under an additive genetic model.
Analyses were adjusted for birth year in order to remove the effect of the temporal decline in
age at menarche. Studies used PLINK, ProABEL, MACH2QTL, SNPTEST, R-packages or
MERLIN-fastassoc for the association testing. The results from individual studies were
corrected by their respective genomic inflation factors (lambda) (Supplementary Table 1)
according to the genomic control (GC) method to correct for population stratification38.
Meta-analysis
We used an inverse-variance meta-analysis to test the effects of each genetic variant on age
at menarche across the 32 studies. Fixed effects models were used, although in the absence
of significant heterogeneity choice of model has little impact on the results. In order to
correct for potential relatedness between two Icelandic cohorts (AGES and deCODE), the
corrected association results for these cohorts were first meta-analysed and the GC method
was re-applied to the results of the combined sample. These results were then meta-analysed
with the remaining 30 studies. We also display further results following a second correction
for GC using the overall genomic inflation factor calculated from the meta-analysis of all 32
studies. All meta-analyses were conducted using the METAL software package. We
considered P-values <5×10−8 to indicate genome-wide significance.
We also meta-analysed results from X chromosome SNPs in a subset of studies with this
data available. This included seven imputed datasets and one directly genotyped. Total
sample size was ~60% of the autosomal meta-analysis (N=52,781), with the same statistical
model tested.
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Conditional analysis
In order to establish whether genome-wide significant SNPs with low LD in the same
chromosomal region (defined as r2<0.05 in a 750 kb region) were independent loci, we
carried out a conditional analysis. Each study performed a genome-wide analysis for age at
menarche using linear regression adjusting for the top signal at each of the 42 associated
regions to determine whether potential second signals remained significant even after
adjusting for these variants. Birth year was also included as a covariate. Results from each
individual study were meta-analysed to determine whether these potential second signals
were truly independent (i.e. if P<5.0×10−8).
Replication studies
In order to confirm our possible novel menarche loci, we tested our 42 top hits for in silico
association with age at menarche in 8,669 women from 16 studies with GWAS data, and
which were not included in the first stage meta-analysis (Supplementary Table 4). In
addition, new genotype data was generated for 30 of the 42 menarche loci and tested for
association with age at menarche in up to 6,118 women from the Avon Longitudinal Study
of Parents and Children (ALSPAC). Genotyping was performed by KBiosciences
(Hoddesdon, UK) using their own novel system of fluorescence-based competitive allele-
specific PCR (KASPar). As in stage 1, analyses were restricted to women reporting age at
menarche between 9 and 17 years, and adjustment was made for birth year. Mean age at
menarche ranged from 12.4 to 13.5 years, consistent with studies in the stage 1 meta-
analysis. Linear regression was used to test the association between each variant and age at
menarche in an additive genetic model. These results were then meta-analysed with GC-
adjusted statistics from our stage 1 meta-analysis using inverse-variance fixed effects
models.
In order to calculate the overall variance explained by these menarche loci in each of the
replication cohorts, we calculated the r2 value from a model including all 42 known,
confirmed and possible novel menarche variants and birth year, and compared this to a
model including birth year alone. We only included cohorts with >800 women in their full
model analyses, as sample sizes smaller than this may give spurious results.
Pathway analysis
Ingenuity Pathway Analysis (IPA) Knowledge Base 8.5 (Ingenuity Systems, CA, USA) was
used to explore the functional relationship between proteins encoded by the 42 known,
confirmed and possible novel menarche loci. The IPA Knowledge base contains millions of
findings curated from the literature. Genes or nearest genes to the 42 loci (as listed in Table
1) were entered into the Ingenuity database. These “focus genes” were analyzed for direct
interactions only. Networks were generated with a maximum size of 35 genes and shown as
graphical representations of the molecular relationships between genes and gene products.
Proteins are depicted as nodes in various shapes representing the functional class of the
protein. The biological relationships between nodes are depicted by lines. To determine the
probability of the analyzed gene to be found together in a network from Ingenuity Pathways
Knowledge Base due to random chance alone, IPA applies a Fisher’s exact test. The
network score or P-value represents the significance of the focus gene enrichment. There are
25 diseases and disorders categories and 32 molecular and cellular function categories in the
IPA Knowledge base. Enrichment of focus genes to these diseases and functional categories
was also evaluated. The P-value, based on a right-tailed Fisher’s exact test, considers the
number of identified focus genes and the total number of molecules known to be associated
with these categories in the IPA knowledge database.
Elks et al. Page 13
Nat Genet. Author manuscript; available in PMC 2011 December 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Meta-Analysis Gene-set Enrichment of variaNT Associations (MAGENTA) was used to
explore pathway-based associations in the full GWAS dataset. MAGENTA implements a
GSEA-based approach, the methodology of which is described in Segrè et al.44. Briefly,
each gene in the genome is mapped to a single index SNP with the lowest P-value within a
110kb upstream, 40kb downstream window. This P-value, representing a gene score, is then
corrected for confounding factors such as gene size, SNP density and LD-related properties
in a regression model. Genes within the HLA-region were excluded from analysis due to
difficulties in accounting for gene density and LD patterns. Each mapped gene in the
genome is then ranked by its adjusted gene score. At a given significance threshold (95th
and 75th percentiles of all gene scores), the observed number of gene scores in a given
pathway, with a ranked score above the specified threshold percentile, is calculated. This
observed statistic is then compared to 1,000,000 randomly permuted pathways of identical
size. This generates an empirical GSEA P-value for each pathway. Significance was
determined when an individual pathway reached a false discovery rate (FDR) < 0.05 in
either analysis (Supplementary table 9). In total, 2529 pathways from Gene Ontology,
PANTHER, KEGG and Ingenuity were tested for enrichment of multiple modest
associations with age at menarche.
eQTLs
We tested the association between 5,184 adipose tissue eSNPs identified in the Icelandic
Family Adipose (IFA) cohort (n=673) with age at menarche in our stage 1 meta-analysis
sample. The IFA cohort dataset included the expression of 23,720 transcripts representing
84% of the 20,060 protein-coding genes annotated in the Ensembl database (v 33)26.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
Academy of Finland (Finnish Centre of Excellence in Complex Disease Genetics 129680, 120315, 129287,
129494); Affymetrix (N02-HL-6-4278); Agency of Science, Technology and Research of Singapore (A*STAR);
Althingi (the Icelandic Parliament); American Heart Association (0855082E); Amgen; Augustinus Foundation;
Australian National Health and Medical Research Council (241944, 339462, 389927, 389875, 389891, 389892,
389938, 442915, 442981, 496739, 552485, 552498, 619667); Australian Research Council (A7960034,
A79801419, A79906588, DP0212016, DP0343921, DP0770096); Baltimore Veterans Administration Medical
Center Geriatrics Research; Canadian Institutes of Health Research (Grant ID 166067); Cancer Research United
Kingdom; the Cariplo Foundation; Center for Disease Control and Prevention (USA), Centre for Medical Systems
Biology (CMSB); the Chief Scientist Office of the Scottish Government; Clinical Nutrition Research Unit of
Maryland (P30 DK072488); Danish National Research Foundation; Danish Pharmacists’ Fund; the Egmont
Foundation; Erasmus Medical Center; Erasmus University; Estonian Government (SF0180142s08); the European
Commision (212111 BBMRI, 205419 ECOGENE, 201413 ENGAGE, HEALTH-F2-2008-201865 - GEFOS,
HEALTH-F2-2008-35627, HEALTH-F4-2007-201413, HEALTH-F4-2007-201550 HYPERGENES, 245536
OPENGENE, TREAT-OA, GenomEUtwin Project QLG2-CT-2002-01254, EU/QLRT-2001-01254; ERC-230374);
European Union framework program 6 EUROSPAN project (LSHG-CT-2006-018947, LSHM-CT-2003-503041);
European Regional Development Fund; Faculty of Biology and Medicine of Lausanne, Switzerland; Fondazione
Compagnia di San Paolo Health Ministry, Framingham Heart Study (N01-HC-25195); GENEVA Coordinating
Center (U01HG004446); German Federal Ministry of Education and Research; German National Genome Research
Network (NGFN-2 and NGFNPlus: 01GS0823); Giorgi-Cavaglieri Foundation; GlaxoSmithKline; Health Fund of
the Danish Health Insurance Societies; Helmholtz Zentrum München - German Research Center for Environmental
Health; Hjartavernd (the Icelandic Heart Association); Italian Ministry of Health (ICS110.1/RF97.71, RF-
FSR-2007-647201); Juvenile Diabetes Research Foundation International (JDRF); Leenaards Foundation; March of
Dimes Birth Defects Foundation; the Medical Research Council (G0000934, G0500539, G0701863); National
Cancer Institute (CA40356, CA98233, P01CA087969, P01CA055075, CA047988, CA63464, CA54281,
CA136792, CA089392, CA104021); Munich Center of Health Sciences (MC Health, LMUinnovativ); National
Health and Medical Research Council of Australia (572613 and 003209); National Heart, Lung, and Blood Institute
(HL 043851, HL087679, HL69757, N01-HC-55015, N01-HC-55016, N01-HC-55018, N01-HC-55019, N01-
HC-55020, N01-HC-55021, N01-HC-55022, R01HL087641, R01HL59367, R01HL086694, RC2 HL102419,);
Elks et al. Page 14
Nat Genet. Author manuscript; available in PMC 2011 December 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
National Human Genome Research Institute (NHGRI); National Institute of Aging (263 MD 9164, 263 MD
821336, N.1-AG-1-1, N.1-AG-1-2111, N01-AG-5-0002, AG-16592, Genetics of Reproductive Life Period and
Health Outcomes - R21AG032598); National Institute of Arthritis Musculoskeletal and Skin Diseases and National
Institute on Aging ((NIAMS/NIA) R01 AR/AG 41398); National Institute of Child Health and Human
Development (HD-061437); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK,
R01DK058845, U01 DK062418); National Institute on Alcohol Abuse and Alcoholism (NIAAA); National
Institute of Allergy and Infectious Diseases (NIAID); National Institute on Drug Abuse (NIDA); National Institutes
of Health (AA07535, AA10248, AA13320, AA13321, AA13326, AA14041, HHSN268200782096C, M01
RR-00750, MH66206, N01-AG-12100, N01-AG-1-2109, P01-AG-18397, R01-088119, R01-DA013423,
RFAHG006033, U01DE018993, U01DE018903, U01HG004422, U01HG004446, U01HL72515, U01 HL84756,
U01HG004399, U01HG004402, U01HG004415, U01HG004423, U01HG004436, U01HG004438, U01HG004402,
U01HG004446, U01HG004726, U01HG004728, U01HG004729, U01HG004735, U01HG004738, U01HG04424,
U10AA008401, U54RR025204-01, UL1RR025005, UL1 RR025774, Z01CP010200, HHSN268200625226C); the
National Institute for Health Research Cambridge Biomedical Research Centre; Netherlands Organization for
Scientific Research (904-61-193, 575-25-006, 480-04-004, 56-464-14192, NWO 480-05-003, 175.010.2005.011,
911-03-012, 014-93-015); Netherlands Genomic Initiative (NGI, 050-060-810), NIA Intramural Research Program;
NIA IRP Laboratory of Neurogenetics; NIH Genes, Environment and Health Initiative; Republic of Croatia
Ministry of Science, Education and Sports (108-1080315-0302); Robert Dawson Evans Endowment; the Royal
Society, Royal Swedish Academy of Science; State of Bavaria, Germany; Susan G. Komen Breast Cancer
Foundation; Swedish Foundation for Strategic Research (SSF); Swedish Heart-Lung Foundation; Swedish Ministry
of Higher Education and Research; Swedish Research Council; Swedish Society of Medicine; Swiss National
Science Foundation (Ref: 33CSCO-122661, 3100AO-116323/1); the University of Bristol, University of Maryland
General Clinical Research Center (M01 RR 16500); the Wellcome Trust (068545/Z/02, 076467/Z/05/Z, 077016/Z/
05/Z, 89061/Z/09/Z, strategic award 079895); Western Australian DNA Bank; Western Australian Genetic
Epidemiology Resource (see Supplementary note for expanded acknowledgements).
References
1. Parent AS, et al. The timing of normal puberty and the age limits of sexual precocity: variations
around the world, secular trends, and changes after migration. Endocr Rev. 2003; 24:668–93.
[PubMed: 14570750]
2. Kvale G. Reproductive factors in breast cancer epidemiology. Acta Oncol. 1992; 31:187–94.
[PubMed: 1622633]
3. Purdie DM, Green AC. Epidemiology of endometrial cancer. Best Pract Res Clin Obstet Gynaecol.
2001; 15:341–54. [PubMed: 11476557]
4. Ong KK, et al. Earlier mother’s age at menarche predicts rapid infancy growth and childhood
obesity. PLoS Med. 2007; 4:e132. [PubMed: 17455989]
5. He C, et al. Age at menarche and risk of type 2 diabetes: results from 2 large prospective cohort
studies. Am J Epidemiol. 2010; 171:334–44. [PubMed: 20026580]
6. Lakshman R, et al. Early age at menarche associated with cardiovascular disease and mortality. J
Clin Endocrinol Metab. 2009; 94:4953–60. [PubMed: 19880785]
7. Towne B, et al. Heritability of age at menarche in girls from the Fels Longitudinal Study. Am J Phys
Anthropol. 2005; 128:210–9. [PubMed: 15779076]
8. He C, et al. Genome-wide association studies identify loci associated with age at menarche and age
at natural menopause. Nat Genet. 2009
9. Ong KK, et al. Genetic variation in LIN28B is associated with the timing of puberty. Nat Genet.
2009
10. Perry JR, et al. Meta-analysis of genome-wide association data identifies two loci influencing age
at menarche. Nat Genet. 2009
11. Sulem P, et al. Genome-wide association study identifies sequence variants on 6q21 associated
with age at menarche. Nat Genet. 2009
12. Raivio T, Dunkel L. Inhibins in childhood and puberty. Best Pract Res Clin Endocrinol Metab.
2002; 16:43–52. [PubMed: 11987897]
13. Crofton PM, et al. Changes in dimeric inhibin A and B during normal early puberty in boys and
girls. Clin Endocrinol (Oxf). 1997; 46:109–14. [PubMed: 9059566]
14. Sehested A, et al. Serum inhibin A and inhibin B in healthy prepubertal, pubertal, and adolescent
girls and adult women: relation to age, stage of puberty, menstrual cycle, follicle-stimulating
Elks et al. Page 15
Nat Genet. Author manuscript; available in PMC 2011 December 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
hormone, luteinizing hormone, and estradiol levels. J Clin Endocrinol Metab. 2000; 85:1634–40.
[PubMed: 10770209]
15. Burger HG. Evidence for a negative feedback role of inhibin in follicle stimulating hormone
regulation in women. Hum Reprod. 1993; 8 (Suppl 2):129–32. [PubMed: 8276946]
16. Sulzbacher S, Schroeder IS, Truong TT, Wobus AM. Activin A-induced differentiation of
embryonic stem cells into endoderm and pancreatic progenitors-the influence of differentiation
factors and culture conditions. Stem Cell Rev. 2009; 5:159–73. [PubMed: 19263252]
17. Dolle P. Developmental expression of retinoic acid receptors (RARs). Nucl Recept Signal. 2009;
7:e006. [PubMed: 19471585]
18. Frayling TM, et al. A common variant in the FTO gene is associated with body mass index and
predisposes to childhood and adult obesity. Science. 2007; 316:889–94. [PubMed: 17434869]
19. Thorleifsson G, et al. Genome-wide association yields new sequence variants at seven loci that
associate with measures of obesity. Nat Genet. 2009; 41:18–24. [PubMed: 19079260]
20. Willer CJ, et al. Six new loci associated with body mass index highlight a neuronal influence on
body weight regulation. Nat Genet. 2009; 41:25–34. [PubMed: 19079261]
21. Sakkou M, et al. A role for brain-specific homeobox factor Bsx in the control of hyperphagia and
locomotory behavior. Cell Metab. 2007; 5:450–63. [PubMed: 17550780]
22. Altarejos JY, et al. The Creb1 coactivator Crtc1 is required for energy balance and fertility. Nat
Med. 2008; 14:1112–7. [PubMed: 18758446]
23. Pissios P, Bradley RL, Maratos-Flier E. Expanding the scales: The multiple roles of MCH in
regulating energy balance and other biological functions. Endocr Rev. 2006; 27:606–20. [PubMed:
16788162]
24. Wu M, Dumalska I, Morozova E, van den Pol A, Alreja M. Melanin-concentrating hormone
directly inhibits GnRH neurons and blocks kisspeptin activation, linking energy balance to
reproduction. Proc Natl Acad Sci U S A. 2009; 106:17217–22. [PubMed: 19805188]
25. Conrad DF, et al. Origins and functional impact of copy number variation in the human genome.
Nature. 2009
26. Emilsson V, et al. Genetics of gene expression and its effect on disease. Nature. 2008; 452:423–8.
[PubMed: 18344981]
27. Kernie SG, Liebl DJ, Parada LF. BDNF regulates eating behavior and locomotor activity in mice.
Embo J. 2000; 19:1290–300. [PubMed: 10716929]
28. Xu B, et al. Brain-derived neurotrophic factor regulates energy balance downstream of
melanocortin-4 receptor. Nat Neurosci. 2003; 6:736–42. [PubMed: 12796784]
29. Temple IK, Shrubb V, Lever M, Bullman H, Mackay DJ. Isolated imprinting mutation of the
DLK1/GTL2 locus associated with a clinical presentation of maternal uniparental disomy of
chromosome 14. J Med Genet. 2007; 44:637–40. [PubMed: 17601927]
30. Drouin J, Lamolet B, Lamonerie T, Lanctot C, Tremblay JJ. The PTX family of homeodomain
transcription factors during pituitary developments. Mol Cell Endocrinol. 1998; 140:31–6.
[PubMed: 9722165]
31. Topaloglu AK, et al. TAC3 and TACR3 mutations in familial hypogonadotropic hypogonadism
reveal a key role for Neurokinin B in the central control of reproduction. Nat Genet. 2009; 41:354–
8. [PubMed: 19079066]
32. Gajdos ZK, et al. Association studies of common variants in 10 hypogonadotropic hypogonadism
genes with age at menarche. J Clin Endocrinol Metab. 2008; 93:4290–8. [PubMed: 18728166]
33. Stavrou I, Zois C, Ioannidis JP, Tsatsoulis A. Association of polymorphisms of the oestrogen
receptor alpha gene with the age of menarche. Hum Reprod. 2002; 17:1101–5. [PubMed:
11925413]
34. Kaprio J, et al. Common genetic influences on BMI and age at menarche. Hum Biol. 1995;
67:739–53. [PubMed: 8543288]
35. Onland-Moret NC, et al. Age at menarche in relation to adult height: the EPIC study. Am J
Epidemiol. 2005; 162:623–32. [PubMed: 16107566]
36. Welt CK, et al. Recombinant human leptin in women with hypothalamic amenorrhea. N Engl J
Med. 2004; 351:987–97. [PubMed: 15342807]
Elks et al. Page 16
Nat Genet. Author manuscript; available in PMC 2011 December 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
37. Pocai A, et al. Restoration of hypothalamic lipid sensing normalizes energy and glucose
homeostasis in overfed rats. J Clin Invest. 2006; 116:1081–91. [PubMed: 16528412]
38. Devlin B, Bacanu SA, Roeder K. Genomic Control to the extreme. Nat Genet. 2004; 36:1129–30.
author reply 1131. [PubMed: 15514657]
39. Manolio TA, et al. Finding the missing heritability of complex diseases. Nature. 2009; 461:747–53.
[PubMed: 19812666]
40. Must A, et al. Recall of early menstrual history and menarcheal body size: after 30 years, how well
do women remember? Am J Epidemiol. 2002; 155:672–9. [PubMed: 11914195]
41. Widen E, et al. Distinct variants at LIN28B influence growth in height from birth to adulthood. Am
J Hum Genet. 86:773–82. [PubMed: 20398887]
42. Herman-Giddens ME, et al. Secondary sexual characteristics and menses in young girls seen in
office practice: a study from the Pediatric Research in Office Settings network. Pediatrics. 1997;
99:505–12. [PubMed: 9093289]
43. Marchini J, Howie B, Myers S, McVean G, Donnelly P. A new multipoint method for genome-
wide association studies by imputation of genotypes. Nat Genet. 2007; 39:906–13. [PubMed:
17572673]
44. Segrè AV, et al. Common inherited variation in mitochondrial genes is not enriched for
associations with type 2 diabetes or related glycemic traits. PLoS Genet. 2010; 6
Elks et al. Page 17
Nat Genet. Author manuscript; available in PMC 2011 December 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Fig. 1.
Flow diagram of the discovery and confirmation of novel loci for age at menarche. GC:
genomic control.
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